Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering (opens original article in a new tab)

Definium Therapeutics announced a $700 million public offering to finance its drug development and commercialization efforts.

• Definium Therapeutics priced a $700 million public offering of 20,588,236 common shares at $34 per share.
• The company may sell an additional 3,088,235 shares within 30 days at the same price.
• Proceeds will fund research, development, and commercialization of psychiatric and neurological treatments.